Roche Holding AG Share Price Swiss Exchange

Equities

RO

CH0012032113

Pharmaceuticals

Real-time Estimate Cboe Europe 14:42:51 19/06/2024 BST 5-day change 1st Jan Change
275.6 CHF +0.36% Intraday chart for Roche Holding AG +2.83% +5.66%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 60.61B 68.56B 5,391B Sales 2025 * 63.99B 72.39B 5,692B Capitalization 200B 227B 17,834B
Net income 2024 * 13.25B 14.99B 1,179B Net income 2025 * 14.74B 16.68B 1,312B EV / Sales 2024 * 3.54 x
Net Debt 2024 * 14.08B 15.93B 1,253B Net Debt 2025 * 9B 10.18B 801B EV / Sales 2025 * 3.27 x
P/E ratio 2024 *
14.9 x
P/E ratio 2025 *
13.4 x
Employees 103,605
Yield 2024 *
3.95%
Yield 2025 *
4.06%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

1 day+0.36%
1 week+2.83%
Current month+9.26%
1 month+6.72%
3 months+14.32%
6 months+6.23%
Current year+5.66%
More quotes
1 week
268.20
Extreme 268.2
276.20
1 month
248.40
Extreme 248.4
276.20
Current year
229.40
Extreme 229.4
277.40
1 year
229.40
Extreme 229.4
302.40
3 years
229.40
Extreme 229.4
439.20
5 years
229.40
Extreme 229.4
439.20
10 years
209.40
Extreme 209.4
439.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 31/12/02
Chairman 57 31/12/07
Director of Finance/CFO 57 31/03/11
Members of the board TitleAgeSince
Director/Board Member 72 02/03/15
Director/Board Member 59 -
Director/Board Member 66 31/12/95
More insiders
Date Price Change Volume
19/06/24 276.2 +0.58% 7 001
18/06/24 274.6 +1.18% 22,354
17/06/24 271.4 -0.80% 26,223
14/06/24 273.6 +0.66% 30,606
13/06/24 271.8 +1.19% 25,985

Delayed Quote Swiss Exchange, June 19, 2024 at 02:19 pm

More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.9 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.16%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW